What is the current price / NAV of Aditya Birla SL Pharma & Healthcare Fund(IDCW-Reinv)?
The current NAV of Aditya Birla SL Pharma & Healthcare Fund(IDCW-Reinv) is ₹23.69, as of 16th July 2025.What are the returns of Aditya Birla SL Pharma & Healthcare Fund(IDCW-Reinv)?
The Aditya Birla SL Pharma & Healthcare Fund(IDCW-Reinv) was launched on 10th July 2019. This mutual fund's past returns are as follows:- 1 Year Returns: 2.78%
- 3 Year Returns: 15.89%
- 5 Year Returns: 12.39%
What are the top 5 sectoral holdings of Aditya Birla SL Pharma & Healthcare Fund(IDCW-Reinv)?
The top sectors Aditya Birla SL Pharma & Healthcare Fund(IDCW-Reinv) has invested in are as follows:- Pharmaceuticals | 75.91%
- Labs & Life Sciences Services | 19.93%
- Others | 1.67%
- Investment Banking & Brokerage | 1.56%
- Diversified Chemicals | 0.92%
What are the top 5 holdings of Aditya Birla SL Pharma & Healthcare Fund(IDCW-Reinv)?
The top 5 holdings for Aditya Birla SL Pharma & Healthcare Fund(IDCW-Reinv) are as follows:- Sun Pharmaceutical Industries Ltd | 11.69%
- Cipla Ltd | 7.65%
- Apollo Hospitals Enterprise Ltd | 7.32%
- Abbott India Ltd | 6.92%
- Torrent Pharmaceuticals Ltd | 5.41%
What is the asset allocation of Aditya Birla SL Pharma & Healthcare Fund(IDCW-Reinv)?
The asset allocation for Aditya Birla SL Pharma & Healthcare Fund(IDCW-Reinv) is as follows:- Equity | 98.42%
- Cash & Equivalents | 1.58%
What is the AUM of Aditya Birla SL Pharma & Healthcare Fund(IDCW-Reinv)?
The AUM (i.e. assets under management) of Aditya Birla SL Pharma & Healthcare Fund(IDCW-Reinv) is ₹840.48 Cr as of 16th July 2025.What is the expense ratio of Aditya Birla SL Pharma & Healthcare Fund(IDCW-Reinv)?
The expense ratio of Aditya Birla SL Pharma & Healthcare Fund(IDCW-Reinv) Plan is 1.04 as of 16th July 2025.What is the alpha ratio of Aditya Birla SL Pharma & Healthcare Fund(IDCW-Reinv)?
The alpha ratio for the Aditya Birla SL Pharma & Healthcare Fund(IDCW-Reinv) is -0.16
Alpha is the excess return of a fund compared to its expected return, based on its beta and the risk-free rate. Positive alpha indicates that the fund has outperformed its expected return, while negative alpha suggests underperformance.
What is the volatility or standard deviation of Aditya Birla SL Pharma & Healthcare Fund(IDCW-Reinv)?
The volatility or standard deviation for the Aditya Birla SL Pharma & Healthcare Fund(IDCW-Reinv) is 14.45
Standard deviation measures the volatility or risk associated with the returns of a mutual fund. A higher standard deviation indicates higher volatility, suggesting that the returns of the mutual fund are more spread out from the average. On the other hand, a lower standard deviation implies lower volatility and a more stable performance.
What is the sharpe ratio of Aditya Birla SL Pharma & Healthcare Fund(IDCW-Reinv)?
The Sharpe ratio for the Aditya Birla SL Pharma & Healthcare Fund(IDCW-Reinv) is 0.45
The Sharpe ratio is a measure of risk-adjusted return that evaluates the performance of a mutual fund, by adjusting for its risk. Higher Sharpe ratio indicates a better risk-adjusted performance. A positive Sharpe ratio indicates that the MF has provided a return in excess of the risk-free rate for the amount of risk taken. Conversely, a negative Sharpe ratio suggests that the MF did not adequately compensate for the risk.
What is the Sortino ratio of Aditya Birla SL Pharma & Healthcare Fund(IDCW-Reinv)?
The Sortino Ratio for the Aditya Birla SL Pharma & Healthcare Fund(IDCW-Reinv) is 0.04
The Sortino ratio of a mutual fund is a measure of its risk-adjusted return, considering only downside volatility. It helps investors evaluate how well a fund is performing relative to its downside risk. A higher Sortino ratio (value >1) means the fund generates better returns for the downside risk taken.
What is the Price to Earnings (PE) ratio of Aditya Birla SL Pharma & Healthcare Fund(IDCW-Reinv)?
The PE ratio of Aditya Birla SL Pharma & Healthcare Fund(IDCW-Reinv) is 47.85, while category PE ratio is 58.49.
Gains are treated as short-term capital gains and taxed at 20%
Gains are treated as long-term capital gains and taxed at 12.5%